Most Popular
-
1
Blinken calls on China to press N. Korea to end its 'dangerous' behavior
-
2
New celebrity-endorsed therapy for face contouring requires only a pair of rubber bands
-
3
Tensions heighten ahead of first president-opposition chief meeting
-
4
[Weekender] How DDP emerged as an icon of Seoul
![[Weekender] How DDP emerged as an icon of Seoul](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/25/20240425050915_0.jpg&u=)
-
5
Seoul to provide housing subsidy to married couples with newborns
![[Weekender] How DDP emerged as an icon of Seoul](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/25/20240425050915_0.jpg&u=)
-
6
Doctor group's incoming head renews call for govt. to scrap medical school quota hike for dialogue
-
7
Rapper jailed after public street fight with another rapper
-
8
NewJeans pops out ‘Bubble Gum’ video amid troubles at agency
-
9
[Music in drama] An ode to childhood trauma
![[Music in drama] An ode to childhood trauma](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/25/20240425050929_0.jpg&u=)
-
10
Woman gets suspended term for injuring boyfriend with knife
![[Music in drama] An ode to childhood trauma](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/25/20240425050929_0.jpg&u=)
Daewoong Pharmaceutical to export Nabota to New Zealand, Israel, Ukraine
By YonhapPublished : Dec. 20, 2018 - 15:59
South Korean drugmaker Daewoong Pharmaceutical Co. said Thursday it has signed deals to sell its type A botulinum toxin drug in New Zealand, Israel and Ukraine.
The product, called Nabota, will be available in the three countries as early as 2020 in accordance with the three separate contracts, whose combined value amounts to $12 million, the company said.
The product, called Nabota, will be available in the three countries as early as 2020 in accordance with the three separate contracts, whose combined value amounts to $12 million, the company said.
Douglas Pharmaceuticals will market Nabota in New Zealand, Israel-based Luminera Derm., Ltd in Israel and Totis Pharma Group in Ukraine, corporate sources said.
"Daewoong Pharmaceutical aims to launch Nabota in over 100 countries by 2020," Park Seong-soo, a company official, said, adding that the company aims to target new and emerging beauty markets.
Nabota -- which is administered via injections -- improves frown lines and arm paralysis by weakening or paralyzing certain muscles or by blocking certain nerves. (Yonhap)
![[Herald Interview] Mistakes turn into blessings in street performance, director says](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/28/20240428050150_0.jpg&u=20240428174656)
